Clinical Trial

Effects of Sitagliptin in Individuals With Genetically Decreased DPP4

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This is a pilot clinical trial to test the hypothesis that during sitagliptin (DPP4 inhibitor), individuals heterozygous for DPP4 loss of function variants will have a reduction in DPP4 activity and antigen, lower glucose after a mixed meal, and higher levels of intact DPP4 substrates compared to during placebo and compared to matched controls.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2020-03-25; most recent amendment 2026-05-05.
Status change: Active, Not Recruiting → Completed 2026-05-05
Status change: Recruiting → Active, Not Recruiting 2025-09-03
Status change: Suspended → Recruiting 2020-08-21
Trial Details
NCT Number NCT04323189
Lead Sponsor University of Pennsylvania
Conditions Genetics Disease, Type2 Diabetes, Heart Failure
Enrollment 20 participants
Start Date 2020-08-26
Primary Completion 2025-02-27 (estimated)
Study Completion 2026-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-01-16